TheraRadar
Data updated: May 26, 2026

MONOKET (isosorbide mononitrate)

Cardiovascular Approved 1993-06-30

MONOKET is indicated for the treatment of Angina Pectoris; Coronary Artery Disease.

Source: FDA Label • OMNIVIUM PHARMS
1
Indication
--
Phase 3 Trials
32
Years on Market

Details

Status
Prescription
First Approved
1993-06-30
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: ISOSORBIDE MONONITRATE

MONOKET Approval History

1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
30 FDA actions from 1993 to 2022
Feb 2022 SUPPL
Mfg · Manufacturing (CMC)
Oct 2014 SUPPL
Label · Labeling
May 2002 SUPPL
Mfg · Manufacturing (CMC)

What MONOKET Treats

2 indications

MONOKET is approved for 2 conditions since its original approval in 1993. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Angina Pectoris
  • Coronary Artery Disease
Source: FDA Label

MONOKET Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to MONOKET

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

NITRO-DUR
NITROGLYCERIN
2 shared
USPHARMA
NITROGLYCERIN
NITROGLYCERIN
2 shared
TP ANDA HOLDINGS
NITROLINGUAL PUMPSPRAY
NITROGLYCERIN
2 shared
POHL BOSKAMP
📋

Clinical Trial Registry

13 trials
Trial Sponsor ID Phase Status Title
NCT07456852 MC250411 NCI-2026-01065, MC250411 Ph 1, Ph 2 not yet recruiting Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy
NCT07252544 2023ZD0504802 Ph 3 not yet recruiting Isosorbide Mononitrate and Butylphthalide to Reduce the Risk of Disability in Patients With Acute Lacunar Stroke (IMPACT)
NCT03544606 ISMN and labor induction Ph 4 completed Nitric Oxide Donor Isosorbide Mono Nitrate for Cervical Ripening in Induction of Labor
NCT02573051 ANP Ph 2 withdrawn Termination Of Anembryonic Pregnancy
NCT04051957 results posted HSC-MS-19-0429 Ph 2 terminated Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury
NCT04729088 CAEP 56.003.19PC Ph 1 withdrawn Pharmacokinetics Trial of Isosorbide Mononitrate 0.5% Gel for Intra Anal Application in Healthy Subjects
NCT04312048 00249 Ph 3 completed the Effect of Isosorbide Mononitrate in Reducing Pain During Cooper Intrauterine Device Insertion
NCT03665779 AN1988 Ph 3 completed Nitric Oxide Donor Isosorbide Mono Nitrate for Induction of Labor With Pre-labor Rupture of Membranes
NCT03407521 R02 MH12345 Ph 4 completed Misoprosotol and Isosorbide Mononitrate for Induction of Second Trimester Abortion
NCT02481323 Prevent-SVD PrevSVD-2015 2015-001953-33, 252 (AS-PG-14-033) Ph 2 completed Lacunar Intervention Trial 1 (LACI-1)
NCT02667535 GDN 001/16 Ph 1 withdrawn PK, PD and Safety Comparative Trial of Isosorbide Mononitrate Gel in Healthy Participants and With Anal Fissure
NCT02053493 NEAT-HFpeF results posted Pro00050042 4U10HL084904-10 Ph 2 completed Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction
NCT02712125 Benha-023 Ph 2, Ph 3 completed Nitric Oxide Donors for Treatment of Isolated Oligohydramnios
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

MONOKET FDA Label Details

Indications & Usage

FDA Label (PDF)

MONOKET is indicated for the treatment of Angina Pectoris; Coronary Artery Disease.

Track MONOKET with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.